Switching To DTG/3TC Vs Continuing B/F/TAF Is Noninferior In Virologically Suppressed Adults Living With HIV At Week 48, Study Suggests

Infectious Disease Advisor (11/22, Basilio) reported, “Switching to dolutegravir/lamivudine (DTG/3TC) vs continuing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is noninferior in virologically suppressed adults living with HIV at week 48, according to study findings.” Researchers found that “serious AEs [adverse events] were reported by 8% and 5% of patients in the DTG/3TC and B/F/TAF arms, respectively, with 1 drug-related serious AE in the DTG/3TC arm.” The findings were published in Open Forum Infectious Diseases.